Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2023 Earnings Conference Call February 28, 2024 8:30 AM ET
Company Participants
Andrew Faughnan - Vice President, Investor Relations
Bradley Campbell - President & Chief Executive Officer
Sebastien Martel - Chief Business Officer
Jeff Castelli - Chief Development Officer
Simon Harford - Chief Financial Officer
Conference Call Participants
Malcolm Kuno - JPMorgan
Ritu Baral - TD Cowen
Dae Gon Ha - Stifel
Joseph Schwartz - Leerink Partners
Ellie Merle - UBS
Jeff Hung - Morgan Stanley
Kristen Kluska - Cantor Fitzgerald
Operator
Good morning ladies and gentlemen and welcome to the Amicus Therapeutics' Full Year 2023 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that. As a reminder, this conference call is being recorded.
I would now like to turn the conference over to your host Mr. Andrew Faughnan, Vice President of Investor Relations. You may begin.
Andrew Faughnan
Great. Thank you, Didi. Good morning. Thank you for everyone. Thank you for joining our conference call to discuss Amicus Therapeutics' full year 2023 financial results and corporate highlights.
Leading today's call we have Bradley Campbell, President and Chief Executive Officer; Sebastien Martel, Chief Business Officer; Simon Harford, Chief Financial Officer; and Dr. Jeff Castelli, Chief Development Officer. Joining for Q&A is Dr. Mitchell Goldman, Chief Medical Officer; and Ellen Rosenberg, Chief Legal Officer.
As referenced on Slide 2, we might make forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business as well as our plans and prospects.
Our forward looking statements should not be regarded as representation by us and any of our plans will be achieved. Any or all the forward-looking statements made on this call may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties.
You are cautioned not to place undue reliance on any forward-looking statements, which speak only to the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and we undertake no obligation to revise or update this presentation and conference call to reflect events or circumstances after the date hereof.
For a full discussion of such forward-looking statements and the risks and uncertainties that may impact them, we refer you to the forward-looking statements and risk factors section of our annual report on Form 10-K for the year ended December 31st, 2023 to be filed today with the Securities and Exchange Commission.